ADC Formulation Development

ADC formulation development focuses on establishing formulation conditions that maintain the molecular integrity, stability, and quality of antibody-drug conjugates throughout processing, storage, and administration. Protheragen provides integrated ADC formulation development services covering formulation screening, buffer and excipient optimization, liquid and lyophilized formulation development, stability evaluation, and formulation process optimization to support ADC candidates from early development through drug product readiness.

Overview of ADC Formulation Development

Antibody-drug conjugates combine a protein-based antibody with a linker and a highly potent small-molecule payload, creating a molecular system with formulation challenges that can differ from those of conventional monoclonal antibodies. Conjugation may introduce additional hydrophobicity and structural heterogeneity, potentially increasing the risk of aggregation, degradation, payload loss, and other changes during storage or processing.

Formulation development therefore requires evaluation of the complete ADC molecule rather than the antibody component alone. Buffer composition, pH, ionic strength, stabilizers, surfactants, concentration, and storage conditions can influence protein conformation, aggregation, particle formation, conjugate integrity, and payload stability.

Both liquid and lyophilized formulations can be considered according to the molecular characteristics and development objectives of the ADC. Lyophilization is widely used for ADC drug products because it can improve long-term stability and reduce some degradation pathways, although the freezing and drying stresses introduced during the process require careful formulation and cycle development.

Fig.1 ADC lyophilization process development and scale-up. (Wang, B.S., et al., 2026)

Our Services

Formulation Development Across ADC Programs

Liquid vs. Lyophilized Formulation Development

The appropriate dosage form depends on the molecular characteristics and development requirements of each ADC program.

Why Choose Protheragen

• ADC-Focused Formulation Strategy

Formulation development considers the combined characteristics of the antibody, linker, payload, conjugation profile, and DAR distribution rather than applying a conventional antibody formulation strategy without modification.

• Integrated Biophysical & Analytical Evaluation

Formulation screening is supported by complementary analytical and biophysical characterization to evaluate aggregation, particles, thermal stability, molecular integrity, and other relevant attributes.

• Flexible Liquid and Lyophilized Development

Both liquid and lyophilized formulation strategies can be evaluated according to the stability profile and development objectives of the ADC candidate.

• Data-Driven Formulation Optimization

Formulation variables and process conditions are systematically evaluated to establish relationships between formulation composition, processing conditions, and product quality.

• Continuity to Drug Product Development

Formulation knowledge generated during development can support subsequent drug product process development, manufacturing, stability studies, and technology transfer.

ADC formulation development requires coordinated consideration of molecular stability, formulation composition, processing conditions, and intended drug product requirements. By integrating formulation screening, excipient optimization, biophysical characterization, stability assessment, and formulation process development, Protheragen supports the establishment of robust formulation strategies for ADC candidates and facilitates their progression toward drug product development and manufacturing. Have an ADC candidate requiring formulation screening, optimization, or lyophilized development? Contact us to discuss your molecule, formulation requirements, development stage, and target dosage form.